Enveric grants 25,000 RSUs to innovation chief

Enveric Biosciences, Inc. granted Chief Innovation Officer Peter J. Facchini 25,000 restricted stock units of common stock under its 2020 Long-Term Incentive Plan.

Rhea-AI Filing Summary

Enveric Biosciences, Inc. granted Chief Innovation Officer Peter J. Facchini 25,000 restricted stock units of common stock under its 2020 Long-Term Incentive Plan. Each unit will convert into one share of common stock as it vests, subject to continued employment.

One-fourth of the RSUs vest after one year, with an additional one-thirty-sixth vesting monthly until any remaining units vest on the fourth anniversary of grant. Following this award, Facchini holds 27,755 shares of common stock, adjusted for a prior 12-for-1 reverse stock split effective October 28, 2025.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Facchini Peter J.

Role Chief Innovation Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 27,755 shares (Direct)

Footnotes (2)

1. F1. Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.
2. F2. On October 28, 2025, the common stock of the Company began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.

Key Figures

RSUs granted: 25,000 units Grant price per share: $0.0000 per share Shares after transaction: 27,755 shares +4 more

7 metrics

RSUs granted 25,000 units Restricted stock units granted to Chief Innovation Officer

Grant price per share $0.0000 per share Reported transaction price for RSU-related common stock

Shares after transaction 27,755 shares Common stock holdings following the RSU grant

Initial vesting portion One-fourth of RSUs Vests on the one-year anniversary of grant

Ongoing vesting rate One-thirty-sixth monthly Vests each month after first anniversary

Final vesting horizon Fourth anniversary Any remaining RSUs vest on this date

Reverse stock split ratio 12-to-1 Common stock reclassified October 28, 2025

Key Terms

restricted stock units, RSUs, 2020 Long-Term Incentive Plan, vesting, +1 more

5 terms

restricted stock units financial

"Represents the restricted stock units (the "RSUs") granted to the reporting person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"For each vested restricted stock unit, the reporting person will be entitled to receive one share"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

2020 Long-Term Incentive Plan financial

"granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended"

vesting financial

"One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Reverse Stock Split financial

"the common stock of the Company began trading on a split-adjusted basis ... (the "Reverse Stock Split")"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Enveric Biosciences (ENVB) report for Peter J. Facchini?

Enveric Biosciences reported a grant of 25,000 restricted stock units to Chief Innovation Officer Peter J. Facchini. These units are part of his equity compensation and will convert into common shares as they vest over time, subject to continued employment.

How do the 25,000 RSUs granted by Enveric Biosciences (ENVB) vest?

The 25,000 RSUs vest with one-fourth on the first anniversary of the grant date, then one-thirty-sixth each month thereafter. Any remaining units fully vest on the fourth anniversary, provided Facchini remains employed by Enveric Biosciences throughout the vesting period.

What will Peter J. Facchini receive for each vested RSU from Enveric Biosciences (ENVB)?

For each vested restricted stock unit, Peter J. Facchini will receive one share of Enveric Biosciences common stock. This structure directly links his potential equity ownership to the company’s share performance and his continued service during the vesting schedule.

How many Enveric Biosciences (ENVB) shares does Peter J. Facchini hold after this RSU grant?

After the RSU award, Peter J. Facchini is reported to hold 27,755 shares of Enveric Biosciences common stock. This figure reflects the company’s 12-for-1 reverse stock split that became effective on October 28, 2025, and is presented on a split-adjusted basis.

What reverse stock split did Enveric Biosciences (ENVB) implement and when?

Enveric Biosciences implemented a 12-for-1 reverse stock split effective October 28, 2025. Every 12 issued and outstanding common shares were reclassified into one share, and the share amounts reported in this insider filing have been adjusted to reflect that reverse split.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 04:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Facchini Peter J.

(Last) (First) (Middle)

C/O ENVERIC BIOSCIENCES, INC.

245 FIRST STREET, RIVERVIEW II, 18TH FL

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enveric Biosciences, Inc. [ ENVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Innovation Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		A		25,000(1)	A	$0	27,755(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan, as amended. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the fourth anniversary of the date of issuance. Vesting is conditioned upon continued employment by the Company.

2. On October 28, 2025, the common stock of the Company began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassified as one share of common stock (the "Reverse Stock Split"). The amount of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Split.

	/s/ Peter J. Facchini	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)